Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioTech adds smaller size to artificial heart bypass graft trial

This article was originally published in Clinica

Executive Summary

CardioTech International has received US FDA approval to add a 4mm graft to the European clinical trial of its artificial heart bypass vessel, CardioPass. The 10-patient study, which started around 15 months ago, previously used only a 5mm graft. Eric Walters, the Wilmington, Massachusetts firm's vice-president and chief financial officer, told Clinica that including the smaller size will widen the pool of patients eligible for enrolment. The firm hopes to report results within a year, which, if positive, will support CE marking of CardioPass for sale in Europe. CardioTech will then consider applying for FDA clearance, Mr Walters said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel